For example, FDA-approved rapamycin analogs such as everolimus, temsirolimus, and tacrolimus, which target FKBP12, have shown the antitumor efficacy in various cancers, including breast cancer, lung cancer and BC 41-43. Here, FKBP1A is linked to breast carcinoma.